WHO-in Covid kai damlo na zual tan Antibody Treatment hman ṭha ti
World Health Organization (WHO) chuan nimin khan Covid-19 kai natna benvawn nei leh taksa lama harsatna nei tan synthe-tic antibody treatment- Regeneron hmang turin thurawn a pe.
Covid-19 kai taksa lama harsatna nei hran lo,mahse damdawi-ina dah ngai te pawhin antibody combo hi an la thei dawn a, hri kai taksa lama harsatna nei taksa dotu khawl chaklo te chuan la ngei se an tih thu WHO zirchianna chuan a tarlang. Regeneron hi WHO-in Covid-19 hri kai enkawlna tura an pawmpui pathumna a ni.
Regeneron synthetic antibodies chawhpawlh - casirivimab leh imdevimab - te hian vaccine la la lo, kum upa emaw immune system chak lote hri vanga damdawi-ina awm theihna chance a tihniam tih clinical trial vawi thum an neihah chuan an tarlang.
WHO pawmpuina hnuaia damlo enkawlna dawngte zirchianna neihah chuan Regeneron damdawi hmang zingah hri vanga thi leh hri kai ventilator hman ngai khawpa taksa chak lote chu an tlakhniam thu an sawi.
Regeneron hi Biotech firm design niin, pharmaceutical giant Roche hnuaiah Ronapreve tih hming chawia zawrh chhuah a ni a, he treatment hi US President kalchhuakta Donald Trump hnenah khan pek a lo ni tawh. Monoclonal antibodies casirivimab leh imdevimab hman kawp hian SARS-CoV-2 spike protein sang tur a veng thei a, hri in kan cell tichhe tur chu enge maw chenin a veng thei a ni.
WHO chuan, "Khawvelin Covid-19 kan dona kawngah ralthuam chak tak kan neih belh leh ta hi a lawmawm hle a ni," a ti a, mahse a man sang chuan ram hrang hrangah inthlauhna a siam leh a hlauthawng hle. UNITAID chuan man tlawm zawk leh awlsam zawka semchhuah a nih theihna atan Roche Pharmaceutical nen inbiakna an nei mek tih a tarlang.